Technology Platforms

ADC Linker-Payload Chemistry

Cleavable linkers, stable linkers, hydrophilic spacers, site-selective handles, and payload-linker intermediate chemistry.

How this supports a project

ADC linker planning must define the antibody attachment site, conjugation handle, spacer, stable or triggered-release motif, payload attachment point, intended loading, and final-conjugate analytics as one system. Payload availability and project scope are confirmed case by case.

Evaluate linker, payload, and conjugation site together

A cleavable or stable label does not fully define an ADC linker. The antibody modification route, conjugation residue or site, reactive handle, payload structure and attachment point, spacer, target loading, and expected released species all affect the complete conjugate.

Linker hydrophobicity, polar surface, PEG or charged elements, and conjugation site can change aggregation, stability, loading distribution, and other properties. Published comparative studies therefore support case-by-case testing of each antibody-linker-payload combination rather than transfer of performance from a named linker motif.

Typical intermediate-planning workflow

1

Define antibody-side chemistry

Specify native or engineered residue, modification route, conjugation site or distribution, reactive group, and intended loading.

2

Define the payload-side connection

Provide payload identity or reference structure, attachment position, functional groups, stereochemistry, hydrophobicity, and handling constraints.

3

Choose stable or release-triggered architecture

For a cleavable design, define the trigger, spacer, self-immolative sequence if used, and expected released species; for a stable design, define the retained catabolite concept.

4

Set spacer and handle

Select hydrophilic or rigid elements and match maleimide, haloacetamide, NHS ester, click, enzymatic, or other handles to the conjugation method.

5

Prepare and characterize intermediates

Confirm structure, identity, purity, stereochemistry where relevant, reactive-handle content, residual reagents, solubility handling, and storage.

6

Qualify the complete conjugate

Measure loading or distribution, conjugation site, free payload, aggregation, purity, bond stability or release, target binding, and project-specific biological performance.

Inputs for platform review

Antibody conjugation format

Lysine, cysteine, engineered site, enzyme tag, glycan, or other method; available handle and target loading.

Payload definition

Exact identity or structure, attachment position, stereochemistry, functional-group constraints, hydrophobicity, and handling requirements.

Linker architecture

Stable or triggered release, trigger mechanism, spacer composition, hydrophilic elements, branching, terminal handle, and expected released species.

Intermediate specification

Required form, scale, purity, analytical methods, residual limits, storage, and whether a linker, linker-payload, or conjugation-ready species is needed.

Final ADC analytical plan

Loading, distribution or site, free payload, aggregation, purity, stability, release, binding, and biological assays.

Where this platform applies

This platform covers linkers, spacers, conjugation handles, and conjugation-ready or payload-linked intermediates when agreed for the project. It does not imply antibody engineering, ADC manufacture, access to any requested payload, a specified drug-to-antibody ratio, biological efficacy, safety, clinical suitability, or regulatory status.

Core considerations

  • Val-Cit, Val-Ala, disulfide, and acid-labile linker patterns
  • MC, SMCC, PEG, and sulfonated spacer options
  • Controlled-loading and site-selective handle selection

Related catalog and technical pages

Sources

  1. 1.Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates (Bioconjugate Chemistry, 2016)
  2. 2.Effect of Linker-Drug Properties and Conjugation Site on the Physical Stability of ADCs (Journal of Pharmaceutical Sciences, 2020)
  3. 3.Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology (Journal of Chromatography B, 2020)
  4. 4.Linker and Conjugation Site Synergy in Antibody-Drug Conjugates: Impacts on Biological Activity (Bioconjugate Chemistry, 2024)